Injectable ecnoglutide (XW003), is a novel, long-acting cAMP-biased GLP-1 receptor agonist designed for the treatment of obesity and T2DM, as well as other obesity related comorbidities. Injectable ecnoglutide (XW003) is potentially the world’s first approved cAMP-biased GLP-1 receptor agonist developed to near-commercialization stage. It selectively activates the cAMP pathway while reducing β-arrestin recruitment, thereby preventing receptor internalization and desensitization to achieve enhanced and sustainable therapeutic efficacy.

XW003 has outstanding clinical excellence with market-leading efficacy in Chinese patients. According to the Phase III clinical data published on Lancet Diabetes & Endocrinology, injectable ecnoglutide (XW003) has demonstrated favorable efficacy in weight loss and glucose-lowering, along with comprehensive benefits in cardiovascular and metabolic risk factors, positioning us as one of the advanced therapeutic options for overweight/obesity and other metabolic diseases.

The New Drug Applications of ecnoglutide injection for both treatment of type 2 diabetes and weight management in overweight/obese patients were accepted by China’s NMPA in 2024.

XW004 is an oral formulation of ecnoglutide, designed for the treatment of obesity and related diseases. XW004 is potentially the world’s first and only weekly long-acting oral cAMP-biased GLP-1 peptide analog and has potential to present injectable-like efficacy.

We have completed Phase I clinical trials for the treatment of obesity in Australia, which demonstrates that XW004 is generally safe and well tolerated and has outstanding efficacy with pronounced weight loss. We have submitted the IND application and will subsequently initiate Phase Ib/IIa clinical trials of XW004 for the treatment of obesity in China in the fourth quarter of 2025. 

XW014 represents our Phase I, oral small molecule cAMP-biased GLP-1 receptor agonist with potential for combination therapies. The compound achieves stable pharmacokinetics with once-daily dosing and exceptional safety profile that minimizes adverse events.

XW014 offers significant manufacturing and formulation advantages compared to peptide-based therapies. As a small molecule, XW014 provides superior production scalability and cost-effectiveness while offering potential for combination therapies with other oral drugs to deliver synergistic therapeutic benefits.

XW015 is a long-acting injectable amylin receptor agonist in the IND stage. Amylin and its analogs show therapeutic potential in both T2DM and obesity by improving glycemic control, enhancing satiety, reducing appetite, and supporting sustained weight loss. By targeting amylin receptors, amylin drugs have the potential for a milder profile of gastrointestinal side effects compared to GLP-1 receptor agonists, particularly nausea and diarrhea.

It can be co-formulated with GLP-1 injectable therapies, a technical advancement that eliminates the need for dual injections or complex devices. Through peptide engineering, we solved the industry-wide co-formulation challenge due to the instability of amylin at neutral pH.

XW016 is the oral amylin peptide analog in development. Amylin and its analogs show therapeutic potential in both T2DM and obesity by improving glycemic control, enhancing satiety, reducing appetite, and supporting sustained weight loss. By targeting amylin receptors, amylin drugs have the potential for a milder profile of gastrointestinal side effects compared to GLP-1 receptor agonists, particularly nausea and diarrhea.

It leverages our proprietary oral delivery technology and optimized fatty acid modifications to achieve high oral bioavailability without compromising therapeutic activity. Studies in non-human primates also validated the feasibility of convenient co-formulated therapy between XW016 and XW004.

XW019 is an early-stage project focused on the development of a monthly injectable biologic designed to deliver body weight reduction and address metabolic disorders. This innovative candidate leverages multiple complementary mechanisms of action to enhance metabolic balance and promote sustained weight reduction, offering the potential for superior efficacy over current competitive molecules. Engineered for extended duration of action, the therapy is optimized for convenient dosing and improved patient adherence, positioning it as a promising next-generation treatment in the obesity and related diseases.

XW020 is a long-acting injectable peptide promoting weight reduction and helping preserve muscle mass. XW020 acts through distinct mechanisms that not only promote body weight reduction but also help preserve muscle mass, addressing a key limitation of many current weight-loss therapies. By maintaining muscle integrity while reducing fat, this candidate has the potential to deliver more balanced and sustainable outcomes for patients. This differentiated mechanism positions XW020 as a promising next-generation high-quality treatment in the evolving obesity care landscape.

XW001 is human interleukin-29 analogue (IL-29), also known as interferon lambda (IFNλ). XW001 was optimized for inhalation. XW001 works by binding to the interferon lambda receptor (IFNλR) on respiratory epithelial cells. XW001 is an inhaled interferon lambda-based therapeutic designed to treat respiratory viral infections — such as RSV, influenza and other respiratory infections with high unmet needs.

We have completed two clinical trials in China for XW001. Clinical results demonstrate that XW001 has a favorable safety profile and is well-tolerated in adult and pediatric populations.